Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.

Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology (Berl) (2007) 0.80

Human models as tools in the development of psychotropic drugs. Dialogues Clin Neurosci (2002) 0.78

Effects of anxiety sensitivity and expectations on the modulation of the startle eyeblink response during a caffeine challenge. Psychopharmacology (Berl) (2015) 0.76

Impact of state and trait anxiety on the panic response to CCK-4. J Neural Transm (Vienna) (2008) 0.76

Anxiety sensitivity and cholecystokinin tetrapeptide challenge. Am J Psychiatry (1995) 0.75

Posttraumatic stress disorder and motor vehicle accidents: a multidisciplinary overview. Can J Psychiatry (1996) 2.15

International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev (1999) 1.74

Progesterone levels on the day of human chorionic gonadotropin administration in cycles with gonadotropin-releasing hormone agonist suppression are not predictive of pregnancy outcome. Fertil Steril (1990) 1.73

The complete nucleotide sequence of the ilvGMEDA cluster of Escherichia coli K-12. Gene (1987) 1.65

Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry (1995) 1.59

Personality dimensions and depression: review and commentary. Can J Psychiatry (1997) 1.52

Tardive dyskinesia: legal and preventive aspects. Can J Psychiatry (1990) 1.47

An expanded anxiety sensitivity index: evidence for a hierarchic structure in a clinical sample. J Anxiety Disord (1999) 1.45

Failure to detect norovirus in a large group of asymptomatic individuals. Public Health (2004) 1.41

Parental bonding and adult psychopathology: results from the US National Comorbidity Survey. Psychol Med (2002) 1.27

Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J Affect Disord (2000) 1.24

Characteristics of problem gambling in a Canadian context: a preliminary study using a DSM-IV-based questionnaire. Can J Psychiatry (1999) 1.16

Adaptive and maladaptive perfectionism in medical students: a longitudinal investigation. Med Educ (2001) 1.15

Heminested multiplex reverse transcription-PCR for detection and differentiation of Norwalk-like virus genogroups 1 and 2 in fecal samples. J Clin Microbiol (2001) 1.14

Anxiety sensitivity: multiple dimensions and hierarchic structure. Behav Res Ther (1998) 1.08

Brief treatment of emergency room patients with panic attacks. Am J Psychiatry (1992) 1.00

Impact of adult attachment styles on pain and disability associated with arthritis in a nationally representative sample. Clin J Pain (2000) 0.99

Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature (1984) 0.98

Suicide among Manitoba's aboriginal people, 1988 to 1994. CMAJ (1997) 0.96

Transposonlike elements in Caedibacter taeniospiralis. J Bacteriol (1986) 0.94

CCK in animal and human research on anxiety. Trends Pharmacol Sci (1993) 0.94

Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry (1999) 0.94

Self-reports of depression and state-trait anxiety: evidence for differential assessment. J Pers Soc Psychol (1992) 0.93

The South Oaks Gambling Screen Revised for Adolescents (SOGS-RA): further psychometric findings from a community sample. J Gambl Stud (2000) 0.92

Extrachromosomal elements of extrachromosomal elements of Paramecium and their extrachromosomal elements. Basic Life Sci (1986) 0.91

Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology (1999) 0.91

Symptoms of PTSD in 124 survivors of the Holocaust. Am J Psychiatry (1992) 0.91

Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety (2012) 0.91

Synthesis and processing of ribosomal RNA in cultured plant cells. Eur J Biochem (1973) 0.91

Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci (1997) 0.89

Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry (1999) 0.89

A retrospective study of the learning history origins of anxiety sensitivity. Behav Res Ther (1998) 0.89

Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci (1997) 0.88

Prevalence of anxiety disorders in elderly adults: a critical analysis. J Behav Ther Exp Psychiatry (1997) 0.88

Causal modeling of relations among learning history, anxiety sensitivity, and panic attacks. Behav Res Ther (2001) 0.88

The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry (1998) 0.87

Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety (1998) 0.87

Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia. Behav Res Ther (1995) 0.86

Phobic dimensions--II. Cross-national confirmation of the multidimensional structure underlying the Mobility Inventory (MI). Behav Res Ther (1995) 0.86

Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol (1991) 0.85

A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) (1992) 0.84

Neurobiology of panic disorder. J Psychosom Res (1998) 0.84

Involvement of a triton-insoluble floating fraction in Dictyostelium cell-cell adhesion. J Biol Chem (2001) 0.84

Confirmatory factor analysis of the Beck Anxiety and Depression Inventories in patients with major depression. J Affect Disord (1998) 0.84

Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci (1991) 0.83

Correlates of analogue and clinical depression: a further test of the phenomenological continuity hypothesis. J Affect Disord (2001) 0.83

A comparison of three assessment instruments for obsessive-compulsive symptoms. J Behav Ther Exp Psychiatry (1994) 0.83

Perfectionism and depression symptom severity in major depressive disorder. Behav Res Ther (1999) 0.83

Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. CMAJ (1992) 0.83

Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry (1996) 0.82

Perceptions of parental bonding and symptom severity in adults with depression: mediation by personality dimensions. Can J Psychiatry (2000) 0.82

Comparative study of refractile (R) bodies and their genetic determinants: relationship of type 51 R bodies to R bodies produced by Pseudomonas taeniospiralis. J Bacteriol (1986) 0.82

A survey of anxiety disorders clinics in Canadian hospitals. Can J Psychiatry (1992) 0.81

Otoneurological functioning in panic disorder patients with prominent dizziness. Compr Psychiatry (1993) 0.81

Multidimensionality of state and trait anxiety: factor structure of the Endler Multidimensional Anxiety Scales. J Pers Soc Psychol (1991) 0.81

Ribosomal RNA genes in the amoebal and plasmodial forms of the slime mould Physarum polycephalum. Eur J Biochem (1975) 0.80

The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. J Psychosom Res (2001) 0.80

CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol (1999) 0.79

Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacol (1995) 0.79

Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry (1992) 0.79

Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.79

High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry (1982) 0.79

MMPI profiles of acute and chronic PTSD in a civilian sample. J Trauma Stress (1996) 0.79

Development of a sensitive and specific assay system for cholecystokinin tetrapeptide. Peptides (1997) 0.79

Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci (1992) 0.79

Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J (1982) 0.78

Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides (1994) 0.78

A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med (2010) 0.78

Precipitating events, locations and reactions associated with initial unexpected panic attacks. Behav Res Ther (1994) 0.78

Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. J Psychopharmacol (1999) 0.78

Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Neuroreport (1995) 0.78

Effect of aging on cholecystokinin-induced panic. Am J Psychiatry (1998) 0.78

Neurobiology of panic disorder. Am J Psychiatry (1989) 0.78

Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy. CNS Drugs (1997) 0.77

A comparison of people with and without nocturnal panic attacks. J Behav Ther Exp Psychiatry (1999) 0.77

An early Phase II clinical trial with followup of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull (1985) 0.77

Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology (1994) 0.77

An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (Berl) (1984) 0.77

Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology (1999) 0.77

The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry (1997) 0.77

A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord (1994) 0.77

The predictive validity of Cluster C personality disorders on the persistence of major depression in the national epidemiologic survey on alcohol and related conditions. J Pers Disord (2012) 0.77

Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol (1985) 0.77

Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Brain Res (1996) 0.77

Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neurosci Lett (2004) 0.77

Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided? J Clin Psychopharmacol (1989) 0.77

Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.77

Behavioral models in mice. Implication of the alpha noradrenergic system. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.76

Anxiety sensitivity and drug choice in individuals seeking treatment for substance abuse. Behav Res Ther (1997) 0.76

Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol (1996) 0.76

Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry (1997) 0.76

Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatry Res (1997) 0.76

Hysterectomy in patients with panic disorder: a failure to replicate. Am J Psychiatry (1993) 0.75

What is behaviour therapy? Can J Psychiatry (1992) 0.75

Using financial incentives to promote shared mental health care. Can J Psychiatry (2002) 0.75

Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry (1995) 0.75

Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies. Clin Neuropharmacol (1992) 0.75

Diagnostic specificity of the dependent and self-critical personality dimensions in major depression. J Affect Disord (1992) 0.75

Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. J Psychiatry Neurosci (1998) 0.75

Relationship of panic disorder to posttraumatic stress disorder. Arch Gen Psychiatry (1995) 0.75